Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

Bayer plc
Bayer House, Strawberry Hill, Newbury, Berkshire, RG14 1JA
Telephone: +44 (0)1635 563 000
Fax: +44 (0)1635 563 393
WWW: http://www.bayer.co.uk

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Summary of Product Characteristics last updated on the eMC: 28/05/2010
SPC Canesten Oasis


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Cystitis Relief

Cystofem

Canesten Oasis

Paramed Cystitis Relief Sachets

Cysto S


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Sodium Citrate Dihydrate BP 4.0g


Go to top of the page
3. PHARMACEUTICAL FORM

Granules to be reconstituted for oral administration.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

For the relief of the symptoms of cystitis in women.


Go to top of the page
4.2 Posology and method of administration

Adult women:

The contents of one sachet dissolved in a glass of water, to be taken three times a day for two days.

Men and children:

Not recommended.


Go to top of the page
4.3 Contraindications

Patients with diabetes, heart disease, hypertension, history of renal disease or those on a low salt diet.

During pregnancy and lactation.


Go to top of the page
4.4 Special warnings and precautions for use

If symptoms persist after the two day course of treatment is completed, medical attention should be sought.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None stated.


Go to top of the page
4.6 Pregnancy and lactation

Contraindicated during pregnancy and lactation.


Go to top of the page
4.7 Effects on ability to drive and use machines

None stated.


Go to top of the page
4.8 Undesirable effects

None stated.


Go to top of the page
4.9 Overdose

In the unlikely event of overdosage occurring with this product, treatment should be symptomatic.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

The effect of sodium citrate is to render the urine less acidic.


Go to top of the page
5.2 Pharmacokinetic properties

None relevant.


Go to top of the page
5.3 Preclinical safety data

None stated.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Sucrose BP (1.5 g)

Colloidal Silicon Dioxide BP

Saccharin Sodium BP

Cranberry Flavouring


Go to top of the page
6.2 Incompatibilities

None stated.


Go to top of the page
6.3 Shelf life

The granules have a three year shelf life.

The reconstituted solution should be used immediately.


Go to top of the page
6.4 Special precautions for storage

Store below 25°C, in dry place.


Go to top of the page
6.5 Nature and contents of container

Foil laminate sachets

or

paper (outer surface layer) /polyethylene (outer layer) /aluminium foil (outer layer) /ionomer resin (inner layer) sachets

Each sachet contains 5.575 g of granule enclosed in a cardboard outer.


Go to top of the page
6.6 Special precautions for disposal and other handling

None stated.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Wrafton Laboratories Limited

Wrafton

Braunton

North Devon

EX33 2DL

United Kingdom


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 12063/0045.


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

4 December 2003.


Go to top of the page
10. DATE OF REVISION OF THE TEXT

26 October 2009.



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/4413/SPC/


Active Ingredients/Generics

 
  sodium citrate dihydrate